Müssig et al. reviewed the prevalence of neuropsychiatric diseases and neuropsychological testing of anti-TPO prevalence for symptomatic distress in HT patients; Degner et al. found significantly elevated anti-TPO in patients with schizophrenia (5.3%) and in those with uni- or bipolar depression (32.7%); and Giynas et al. showed that "their HT group exhibited a substantially increased prevalence of depression, obsessional compulsive disorder, and panic disorder compared to their control group” [14,26,27]. The gene discussed is TPO; the disease is schizophrenia.